Although a previous study by Patel et al.6 did not find differences in overall survival between IDH-mutant glioma patients with versus without a T2/FLAIR-mismatch sign, both ADC and rCBV are well-known prognostic factors in patients with gliomas.24–26 Future studies should therefore investigate whether the quantifiable differences in the ADC and rCBV values in our study may also translate into a clinically measurable prognostic effect with a better outcome for those IDH-mutant gliomas with the presence of a T2/FLAIR-mismatch sign. This evidence concerns the gene IDH1 and central nervous system cancer.